Therapeutic cancer vaccines based on molecularly defined human tumor antigens.
Détails
ID Serval
serval:BIB_A1891852C369
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Therapeutic cancer vaccines based on molecularly defined human tumor antigens.
Périodique
Vaccine
ISSN
0264-410X
Statut éditorial
Publié
Date de publication
2002
Peer-reviewed
Oui
Volume
20 Suppl 4
Pages
A2-7
Langue
anglais
Notes
Publication types: Journal Article - Publication Status: ppublish
Résumé
The results of numerous phases I and II clinical trials testing the safety and immunogenicity of various cancer vaccine formulations based on cytolytic T lymphocytes (CTLs)-defined tumor antigens have been reported recently. Specific T cell responses can be detected in only a fraction of immunized patients. A smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring anti-tumor responses and at sustaining a large contingent of tumor antigen-specific and fully functional effector T cells at tumor sites.
Mots-clé
Antigens, Neoplasm, Cancer Vaccines, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Humans, T-Lymphocytes, Cytotoxic
Pubmed
Web of science
Création de la notice
28/01/2008 12:14
Dernière modification de la notice
20/08/2019 16:07